An IL-7 fusion protein targeting EDA fibronectin upregulates TCF1 on CD8+ T-cells, preferentially accumulates to neoplastic lesions, and boosts PD-1 blockade
Our results provide the rationale to explore the combination of F8(scDb)-IL7 with anti-PD-1 antibodies for the treatment of patients with cancer.
Authors
- Ettore Gilardoni (ORCID: https://orcid.org/0000-0002-2010-2667)
- Markus Gabriel Manz (ORCID: https://orcid.org/0000-0002-4676-7931)
- Eleonora Prodi
- Tobias Weiß (ORCID: https://orcid.org/0000-0002-5533-9429)
- Michael Weller (ORCID: https://orcid.org/0000-0002-1748-174X)
- Roberto De Luca (ORCID: https://orcid.org/0000-0001-7519-8689)
- Vlad Moisoiu (ORCID: https://orcid.org/0000-0001-7244-5082)
- Thomas Look (ORCID: https://orcid.org/0000-0001-5410-6220)
- Emanuele Puca (ORCID: https://orcid.org/0000-0002-2869-3203)
- Cesare Di Nitto (ORCID: https://orcid.org/0009-0000-9138-8503)
- Christian Pellegrino (ORCID: https://orcid.org/0000-0001-7898-9988)
- Domenico Ravazza (ORCID: https://orcid.org/0009-0006-5739-8090)
- Miaomiao Sun (ORCID: https://orcid.org/0009-0008-5737-0519)
- Dario Neri
Institutions
- University of Zurich (CH)
- ETH Zurich (CH)
- University Hospital of Zurich (CH)
- Philogen (Italy) (IT)
- Philochem (Switzerland) (CH)
Publication Details
- Journal
- Journal for ImmunoTherapy of Cancer
- Published
- 2024-08-01
- DOI
- https://doi.org/10.1136/jitc-2023-008504
- Citations
- 8
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 2.26